Katherine Weh

Dr. Katherine Weh

University of Michigan
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
GCGang Cheng
Gang Cheng
QZQi Zhang
Qi Zhang
JPJing Pan
Jing Pan
YLYongik Lee
Yongik Lee
OOOlivier Ouari
Olivier Ouari
MYMing You
Ming You
Lung cancer often has a poor prognosis, with brain metastases a major reason for mortality. We modified lonidamine (LND), an antiglycolytic drug with limited efficacy, to mitochondria-targeted mito-lonidamine (Mito-LND) which is 100-fold more potent. Mito-LND, a tumor-selective inhibitor of oxidative phosphorylation, inhibits mitochondrial bioenergetics in lung cancer cells and mitigates lung cancer cell viability, growth, progression, and metastasis of lung cancer xenografts in mice. Mito-LND blocks lung tumor development and brain metastasis by inhibiting mitochondrial bioenergetics, stimulating the formation of reactive oxygen species, oxidizing mitochondrial peroxiredoxin, inactivating AKT/mTOR/p70S6K signaling, and inducing autophagic cell death in lung cancer cells. Mito-LND causes no toxicity in mice even when administered for eight weeks at 50 times the effective cancer inhibitory dose. Collectively, these findings show that mitochondrial targeting of LND is a promising therapeutic approach for investigating the role of autophagy in mitigating lung cancer development and brain metastasis.

10 September 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
Laura KrestyLaura Kresty
Laura Kresty
KWKatherine Weh
Katherine Weh
BZBree Zeyzus-Johns
Bree Zeyzus-Johns
LPLaura N. Perez
Laura N. Perez
AHAmy B. Howell
Amy B. Howell
Cranberry proanthocyanidins inhibit esophageal adenocarcinoma in vitro and in vivo through pleiotropic cell death induction and PI3K/AKT/mTOR inactivation

18 August 2016 in Antioxidants
Verified
Journal Article
Open access
PDF file
KWKatherine Weh
Katherine Weh
JCJennifer Clarke
Jennifer Clarke
Laura KrestyLaura Kresty
Laura Kresty
Cranberries are rich in bioactive constituents reported to influence a variety of health benefits, ranging from improved immune function and decreased infections to reduced cardiovascular disease and more recently cancer inhibition. A review of cranberry research targeting cancer revealed positive effects of cranberries or cranberry derived constituents against 17 different cancers utilizing a variety of in vitro techniques, whereas in vivo studies supported the inhibitory action of cranberries toward cancers of the esophagus, stomach, colon, bladder, prostate, glioblastoma and lymphoma. Mechanisms of cranberry-linked cancer inhibition include cellular death induction via apoptosis, necrosis and autophagy; reduction of cellular proliferation; alterations in reactive oxygen species; and modification of cytokine and signal transduction pathways. Given the emerging positive preclinical effects of cranberries, future clinical directions targeting cancer or premalignancy in high risk cohorts should be considered.

19 November 2015 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
KWKatherine Weh
Katherine Weh
AHAmy B. Howell
Amy B. Howell
Laura KrestyLaura Kresty
Laura Kresty

8 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
KWKatherine Weh
Katherine Weh
CHConnor Howard
Connor Howard
YZYun Zhang
Yun Zhang
BTBridget A. Tripp
Bridget A. Tripp
JCJennifer Clarke
Jennifer Clarke
Laura KrestyLaura Kresty
Laura Kresty
The gut and local esophageal microbiome progressively shift from healthy commensal bacteria to inflammation-linked pathogenic bacteria in patients with gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma (EAC). However, mechanisms by which microbial communities and metabolites contribute to reflux-driven EAC remain incompletely understood and challenging to target. Herein, we utilized a rat reflux-induced EAC model to investigate targeting the gut microbiome–esophageal metabolome axis with cranberry proanthocyanidins (C-PAC) to inhibit EAC progression. Sprague-Dawley rats, with or without reflux induction, received water or C-PAC ad libitum (700 μg/rat/day) for 25 or 40 weeks. C-PAC exerted prebiotic activity abrogating reflux-induced dysbiosis and mitigating bile acid metabolism and transport, culminating in significant inhibition of EAC through TLR/NF-κB/TP53 signaling cascades. At the species level, C-PAC mitigated reflux-induced pathogenic bacteria ( Streptococcus parasanguinis , Escherichia coli , and Proteus mirabilis ). C-PAC specifically reversed reflux-induced bacterial, inflammatory, and immune-implicated proteins and genes, including Ccl4 , Cd14 , Crp , Cxcl1 , Il6 , Il1b , Lbp , Lcn2 , Myd88 , Nfkb1 , Tlr2 , and Tlr4 , aligning with changes in human EAC progression, as confirmed through public databases. C-PAC is a safe, promising dietary constituent that may be utilized alone or potentially as an adjuvant to current therapies to prevent EAC progression through ameliorating reflux-induced dysbiosis, inflammation, and cellular damage.

17 September 2020 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
GCGang Cheng
Gang Cheng
MHMicael Hardy
Micael Hardy
JZJacek Zielonka
Jacek Zielonka
KWKatherine Weh
Katherine Weh
MZMonika Zielonka
Monika Zielonka
BKBalaraman Kalyanaraman
Balaraman Kalyanaraman
Melanoma is an aggressive form of skin cancer for which there are no effective drugs for prolonged treatment. The existing kinase inhibitor antiglycolytic drugs (B-Raf serine/threonine kinase or BRAF inhibitors) are effective for a short time followed by a rapid onset of drug resistance. Here, we show that a mitochondria-targeted analog of magnolol, Mito-magnolol (Mito-MGN), inhibits oxidative phosphorylation (OXPHOS) and proliferation of melanoma cells more potently than untargeted magnolol. Mito-MGN also inhibited tumor growth in murine melanoma xenografts. Mito-MGN decreased mitochondrial membrane potential and modulated energetic and mitophagy signaling proteins. Results indicate that Mito-MGN is significantly more potent than the FDA-approved OXPHOS inhibitor in inhibiting proliferation of melanoma cells. These findings have implications in the treatment of melanomas with enhanced OXPHOS status due to metabolic reprogramming or drug resistance.